Can we identify patients carrying targeted deleterious
DPYD
dihydrouracil
genotype
phenotype
uracil
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
08
03
2024
accepted:
04
06
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of severe fluoropyrimidine-related toxicities. The best strategy for identifying DPD-deficient patients is still not defined. The EMA recommends targeted This study included 19,376 consecutive French patients with pre-treatment plasma U, UH2 and targeted Mean U was 9.9 ± 10.1 ng/mL (median 8.7, range 1.6-856). According to French recommendations, 7.3 % of patients were partially deficient (U 16-150 ng/mL) and 0.02 % completely deficient (U≥150 ng/mL). These results reaffirm the poor concordance between DPD phenotyping and genotyping, suggesting that both approaches may be complementary and that targeted
Identifiants
pubmed: 38896022
pii: cclm-2024-0317
doi: 10.1515/cclm-2024-0317
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Walter de Gruyter GmbH, Berlin/Boston.
Références
Grothey, A, Sobrero, AF, Shields, AF, Yoshino, T, Paul, J, Taieb, J, et al.. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177–88. https://doi.org/10.1056/nejmoa1713709 .
doi: 10.1056/nejmoa1713709
Sharma, BB, Rai, K, Blunt, H, Zhao, W, Tosteson, TD, Brooks, GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncol 2021;26:1008–16. https://doi.org/10.1002/onco.13967 .
doi: 10.1002/onco.13967
Diasio, RB, Harris, BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215–37. https://doi.org/10.2165/00003088-198916040-00002 .
doi: 10.2165/00003088-198916040-00002
van Kuilenburg, ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939–50. https://doi.org/10.1016/j.ejca.2003.12.004 .
doi: 10.1016/j.ejca.2003.12.004
Etienne-Grimaldi, M-C, Pallet, N, Boige, V, Ciccolini, J, Chouchana, L, Barin-Le Guellec, C, et al.. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. Eur J Cancer 2023;181:3–17. https://doi.org/10.1016/j.ejca.2022.11.028 .
doi: 10.1016/j.ejca.2022.11.028
Etienne, MC, Lagrange, JL, Dassonville, O, Fleming, R, Thyss, A, Renée, N, et al.. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248–53. https://doi.org/10.1200/jco.1994.12.11.2248 .
doi: 10.1200/jco.1994.12.11.2248
Pallet, N, Hamdane, S, Garinet, S, Blons, H, Zaanan, A, Paillaud, E, et al.. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. Br J Cancer 2020;123:811–8. https://doi.org/10.1038/s41416-020-0962-z .
doi: 10.1038/s41416-020-0962-z
Knikman, JE, Gelderblom, H, Beijnen, JH, Cats, A, Guchelaar, H-J, Henricks, LM. Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther 2021;109:591–604. https://doi.org/10.1002/cpt.2069 .
doi: 10.1002/cpt.2069
Paulsen, NH, Qvortrup, C, Vojdeman, FJ, Plomgaard, P, Andersen, SE, Ramlov, A, et al.. Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations. Acta Oncol 2022;61:1400–5. https://doi.org/10.1080/0284186x.2022.2132117 .
doi: 10.1080/0284186x.2022.2132117
Laures, N, Konecki, C, Brugel, M, Giffard, A-L, Abdelli, N, Botsen, D, et al.. Impact of guidelines regarding dihydropyrimidine dehydrogenase (DPD) deficiency screening using uracil-based phenotyping on the reduction of severe side effect of 5-fluorouracil-based chemotherapy: a propension score analysis. Pharmaceutics 2022;14:2119. https://doi.org/10.3390/pharmaceutics14102119 .
doi: 10.3390/pharmaceutics14102119
Thomas, F, Launay, M, Guitton, J, Loriot, M-A, Boyer, J-C, Haufroid, V, et al.. Plasma uracil as a DPD phenotyping test: pre-analytical handling matters. Clin Pharmacol Ther 2023;113:471–2. https://doi.org/10.1002/cpt.2772 .
doi: 10.1002/cpt.2772
Boisdron-Celle, M, Remaud, G, Traore, S, Poirier, AL, Gamelin, L, Morel, A, et al.. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271–82. https://doi.org/10.1016/j.canlet.2006.09.006 .
doi: 10.1016/j.canlet.2006.09.006
Etienne-Grimaldi, M-C, Boyer, J-C, Beroud, C, Mbatchi, L, Kuilenburg, Avan, Bobin-Dubigeon, C, et al.. New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS One 2017;12:e0175998. https://doi.org/10.1371/journal.pone.0175998 .
doi: 10.1371/journal.pone.0175998
Meulendijks, D, Henricks, LM, Jacobs, BAW, Aliev, A, Deenen, MJ, de Vries, N, et al.. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 2017;116:1415–24. https://doi.org/10.1038/bjc.2017.94 .
doi: 10.1038/bjc.2017.94
HAS, INCa. Recherche de déficit en dihydropyrimidine déshydrogénase en vue de prévenir certaines toxicités sévères survenant sous traitement comportant des fluoropyrimidines [Internet] , Paris; 2018. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2018-12/recherche_dun_deficit_en_dihydropyrimidine_deshydrogenase_visant_a_prevenir_certaines_toxicites_severes_associees_aux_traite.pdf .
European Medicines Agency . Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products - referral [Internet] . European Medicines Agency, Amsterdam; 2020. [cited 2024 Jan 29]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/fluorouracil-and-fluorouracil-related-substances-capecitabine-tegafur-and-flucytosine-containing-medicinal-products .
Maillard, M, Launay, M, Royer, B, Guitton, J, Gautier-Veyret, E, Broutin, S, et al.. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol 2023;89:762–72. https://doi.org/10.1111/bcp.15536 .
doi: 10.1111/bcp.15536
Loison, G, Bouges Le Royer, H, Marsili, S, Brice, A, Vintejoux, J, Yakoubi, M, et al.. Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing. Clin Chem Lab Med 2024. https://doi.org/10.1515/cclm-2023-1096 .
doi: 10.1515/cclm-2023-1096
Thomas, F, Maillard, M, Launay, M, Tron, C, Etienne-Grimaldi, M-C, Gautier-Veyret, E, et al.. Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. Ann Oncol 2021;32:810–1. https://doi.org/10.1016/j.annonc.2021.02.020 .
doi: 10.1016/j.annonc.2021.02.020
Royer, B, Launay, M, Ciccolini, J, Derain, L, Parant, F, Thomas, F, et al.. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. ESMO Open 2023;8:101577. https://doi.org/10.1016/j.esmoop.2023.101577 .
doi: 10.1016/j.esmoop.2023.101577
Arrivé, C, Fonrose, X, Thomas, F, Roth, G, Jacquet, E, Brice, A, et al.. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: what are the explanatory factors? Br J Clin Pharmacol 2023;89:2446–57. https://doi.org/10.1111/bcp.15715 .
doi: 10.1111/bcp.15715
Launay, M, Guitton, J, Balluet, R, Moreau, A, Phelip, J-M, Tholance, Y, et al.. Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference. Ann Oncol 2022;33:850–2. https://doi.org/10.1016/j.annonc.2022.04.073 .
doi: 10.1016/j.annonc.2022.04.073
Jiang, H, Lu, J, Ji, J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004;141:616–23. https://doi.org/10.1038/sj.bjp.0705651 .
doi: 10.1038/sj.bjp.0705651
Henricks, LM, Jacobs, BAW, Meulendijks, D, Pluim, D, van den Broek, D, de Vries, N, et al.. Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. Br J Clin Pharmacol 2018;84:2761–9. https://doi.org/10.1111/bcp.13719 .
doi: 10.1111/bcp.13719
Offer, SM, Fossum, CC, Wegner, NJ, Stuflesser, AJ, Butterfield, GL, Diasio, RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 2014;74:2545–54. https://doi.org/10.1158/0008-5472.can-13-2482 .
doi: 10.1158/0008-5472.can-13-2482
Amstutz, U, Henricks, LM, Offer, SM, Barbarino, J, Schellens, JHM, Swen, JJ, et al.. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018;103:210–6. https://doi.org/10.1002/cpt.911 .
doi: 10.1002/cpt.911
Meulendijks, D, Henricks, LM, Sonke, GS, Deenen, MJ, Froehlich, TK, Amstutz, U, et al.. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:1639–50. https://doi.org/10.1016/s1470-2045(15)00286-7 .
doi: 10.1016/s1470-2045(15)00286-7
Le Teuff, G, Cozic, N, Boyer, J-C, Boige, V, Diasio, RB, Taieb, J, et al.. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. Br J Cancer 2024;130:808–18. https://doi.org/10.1038/s41416-023-02517-2 .
doi: 10.1038/s41416-023-02517-2
Nie, Q, Shrestha, S, Tapper, EE, Trogstad-Isaacson, CS, Bouchonville, KJ, Lee, AM, et al.. Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clin Pharmacol Ther 2017;102:662–70. https://doi.org/10.1002/cpt.685 .
doi: 10.1002/cpt.685
Henricks, LM, Lunenburg, CATC, de Man, FM, Meulendijks, D, Frederix, GWJ, Kienhuis, E, et al.. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018;19:1459–67. https://doi.org/10.1016/s1470-2045(18)30686-7 .
doi: 10.1016/s1470-2045(18)30686-7
Lee, AM, Shi, Q, Alberts, SR, Sargent, DJ, Sinicrope, FA, Berenberg, JL, et al.. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenetics Genom 2016;26:133–7. https://doi.org/10.1097/fpc.0000000000000197 .
doi: 10.1097/fpc.0000000000000197
Knikman, JE, Wilting, TA, Lopez-Yurda, M, Henricks, LM, Lunenburg, CATC, de Man, FM, et al.. Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy-A matched-pair analysis. J Clin Oncol 2023;41:5411–21. https://doi.org/10.1200/jco.22.02780 .
doi: 10.1200/jco.22.02780
de With, M, Sadlon, A, Cecchin, E, Haufroid, V, Thomas, F, Joerger, M, et al.. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open 2023;8:101197. https://doi.org/10.1016/j.esmoop.2023.101197 .
doi: 10.1016/j.esmoop.2023.101197
de With, M, Brufau, G, van den Berg, LA, de Man, FM, Trajkovic, M, Thijs, MF, et al.. DPYD*7 as a predictor of severe fluoropyrimidine-related adverse events. JCO Precis Oncol 2022;6:e2200180. https://doi.org/10.1200/po.22.00180 .
doi: 10.1200/po.22.00180
Casneuf, V, Borbath, I, Van den Eynde, M, Verheezen, Y, Demey, W, Verstraete, AG, et al.. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clin Belg 2022;77:346–52. https://doi.org/10.1080/17843286.2020.1870855 .
doi: 10.1080/17843286.2020.1870855
Vreken, P, Van Kuilenburg, AB, Meinsma, R, De Abreu, RA, Van Gennip, AH. Identification of a four-base deletion (delTCAT296-299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression. Hum Genet 1997;100:263–5. https://doi.org/10.1007/s004390050502 .
doi: 10.1007/s004390050502
Hamzic, S, Schärer, D, Offer, SM, Meulendijks, D, Nakas, C, Diasio, RB, et al.. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: implication for 5-fluorouracil toxicity. Br J Clin Pharmacol 2021;87:3234–43. https://doi.org/10.1111/bcp.14742 .
doi: 10.1111/bcp.14742
Larrue, R, Fellah, S, Hennart, B, Sabaouni, N, Boukrout, N, Van der Hauwaert, C, et al.. Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity. Pharmacogenomics J 2024;24:1. https://doi.org/10.1038/s41397-023-00322-x .
doi: 10.1038/s41397-023-00322-x
Poumeaud, F, Dalenc, F, Mathevet, Q, Brice, A, Eche-Gass, A, De Maio, D, et al.. Phenotype/genotype discrepancy of DPD deficiency screening in a patient with severe capecitabine toxicity: a case report. JCO Precis Oncol 2023;7:e2200508. https://doi.org/10.1200/po.22.00508 .
doi: 10.1200/po.22.00508
Gbeto, CC, Quaranta, S, Mari, R, Fanciullino, R, Roche, C, Nahon, S, et al.. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. Pharmacogenomics 2019;20:931–8. https://doi.org/10.2217/pgs-2019-0028 .
doi: 10.2217/pgs-2019-0028
Henricks, LM, Siemerink, EJM, Rosing, H, Meijer, J, Goorden, SMI, Polstra, AM, et al.. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. Int J Cancer 2018;142:424–30. https://doi.org/10.1002/ijc.31065 .
doi: 10.1002/ijc.31065
Morel, A, Boisdron-Celle, M, Fey, L, Lainé-Cessac, P, Gamelin, E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007;40:11–7. https://doi.org/10.1016/j.clinbiochem.2006.07.012 .
doi: 10.1016/j.clinbiochem.2006.07.012
van Kuilenburg, AB, Muller, EW, Haasjes, J, Meinsma, R, Zoetekouw, L, Waterham, HR, et al.. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001;7:1149–53.
Launay, M, Dahan, L, Duval, M, Rodallec, A, Milano, G, Duluc, M, et al.. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol 2016;81:124–30. https://doi.org/10.1111/bcp.12790 .
doi: 10.1111/bcp.12790
Dolat, M, Macaire, P, Goirand, F, Vincent, J, Hennequin, A, Palmier, R, et al.. Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure. Pharmaceuticals 2020;13:416. https://doi.org/10.3390/ph13110416 .
doi: 10.3390/ph13110416
Beumer, JH, Chu, E, Allegra, C, Tanigawara, Y, Milano, G, Diasio, R, et al.. Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther 2019;105:598–613. https://doi.org/10.1002/cpt.1124 .
doi: 10.1002/cpt.1124